Amedisys Inc (NASDAQ:AMED) insider David L. Kemmerly sold 6,500 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $118.87, for a total value of $772,655.00. The transaction was disclosed in a filing with the SEC, which is available through this link.
David L. Kemmerly also recently made the following trade(s):
- On Wednesday, November 7th, David L. Kemmerly sold 3,375 shares of Amedisys stock. The shares were sold at an average price of $117.44, for a total value of $396,360.00.
Amedisys stock traded up $1.46 during mid-day trading on Friday, hitting $120.50. The company’s stock had a trading volume of 476,700 shares, compared to its average volume of 343,222. The company has a market capitalization of $3.57 billion, a PE ratio of 54.53, a price-to-earnings-growth ratio of 1.67 and a beta of 1.22. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.12. Amedisys Inc has a one year low of $49.80 and a one year high of $127.38.
Amedisys (NASDAQ:AMED) last announced its quarterly earnings data on Monday, October 29th. The health services provider reported $0.95 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.18. The company had revenue of $417.34 million for the quarter, compared to the consensus estimate of $411.05 million. Amedisys had a return on equity of 23.27% and a net margin of 5.39%. Amedisys’s quarterly revenue was up 11.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.56 EPS. As a group, research analysts anticipate that Amedisys Inc will post 3.58 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its position in Amedisys by 11.0% in the 3rd quarter. Janus Henderson Group PLC now owns 4,745 shares of the health services provider’s stock valued at $593,000 after acquiring an additional 471 shares during the last quarter. Aperio Group LLC grew its position in shares of Amedisys by 2.7% during the 3rd quarter. Aperio Group LLC now owns 18,559 shares of the health services provider’s stock worth $2,319,000 after buying an additional 480 shares in the last quarter. Amalgamated Bank grew its position in shares of Amedisys by 13.7% during the 2nd quarter. Amalgamated Bank now owns 4,667 shares of the health services provider’s stock worth $399,000 after buying an additional 563 shares in the last quarter. Piedmont Investment Advisors LLC grew its position in shares of Amedisys by 9.3% during the 2nd quarter. Piedmont Investment Advisors LLC now owns 6,668 shares of the health services provider’s stock worth $570,000 after buying an additional 567 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its position in shares of Amedisys by 6.9% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,282 shares of the health services provider’s stock worth $793,000 after buying an additional 596 shares in the last quarter. 93.58% of the stock is currently owned by institutional investors.
AMED has been the topic of several analyst reports. SunTrust Banks boosted their target price on Amedisys to $130.00 and gave the company a “buy” rating in a research report on Thursday, October 11th. Bank of America set a $139.00 target price on Amedisys and gave the company a “buy” rating in a research report on Tuesday, September 18th. BidaskClub downgraded Amedisys from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 16th. Benchmark raised Amedisys from a “hold” rating to a “buy” rating and set a $125.00 target price on the stock in a research report on Tuesday, October 30th. Finally, Craig Hallum downgraded Amedisys from a “buy” rating to a “hold” rating and cut their target price for the company from $116.00 to $104.00 in a research report on Friday, October 26th. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Amedisys presently has an average rating of “Buy” and an average price target of $105.50.
Amedisys Company Profile
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.
Further Reading: Understanding Analyst Ratings
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.